Carcinoma, Intraductal, Noninfiltrating clinical trials
The registry lists 286 studies for Carcinoma, Intraductal, Noninfiltrating across more than 10 countries. 55 are recruiting or about to start. 211 of them are mainly about Carcinoma, Intraductal, Noninfiltrating (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-13.
Get an email when these change. Save the Carcinoma, Intraductal, Noninfiltrating studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Cancer Institute (NCI) (13) · M.D. Anderson Cancer Center (9) · Ohio State University Comprehensive Cancer Center (8) · Mayo Clinic (8) · Dana-Farber Cancer Institute (7) · Northwestern University (7) · Wake Forest University Health Sciences (7) · Alliance for Clinical Trials in Oncology (6)
What is being tested here
Drugs under test in Carcinoma, Intraductal, Noninfiltrating studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Tamoxifen | 4 | 5 | 16 |
| Anastrozole | 2 | 2 | 7 |
| Endoxifen | 1 | 0 | 2 |
| Darolutamide | 1 | 0 | 1 |
| Degarelix | 1 | 0 | 1 |
| Testosterone | 1 | 0 | 1 |
| Elacestrant | 1 | 0 | 1 |
| MUC-1 Peptide Vaccine | 1 | 0 | 1 |
| TLR7 Agonist CAN1012 | 1 | 0 | 1 |
| Acolbifene | 1 | 0 | 1 |
Drug classes tested here SERMs 4 open · Aromatase inhibitors 2 open · Tyrosine kinase inhibitors (TKIs) 4 · Statins 4
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Dec 2026Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ · Phase 3 · Uppsala University
- Nov 2026Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ · Glendale Adventist Medical Center d/b/a Adventist Health Glendale
- Nov 2026Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants · M.D. Anderson Cancer Center
- Dec 2026Breast Tumour Size Measurement by Field Cycling Imaging · University of Aberdeen
- Dec 2026Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma · Stanford University
- Dec 2026The PREDICT Registry: · PreludeDx
- Dec 2026Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer · City of Hope Medical Center
- Dec 2026Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer. · Coordinación de Investigación en Salud, Mexico
- Dec 2026Human-AI Collaborative INSIGHT Diagnostic Workflow for in Breast Cancer With Extensive Intraductal Component · Sun Yat-sen University
- Dec 2026The Added Value of Contrast Enhanced Mammography to Standard Mammography in Assessing the Extent of DCIS · Clinical Hospital Center Rijeka
Who these studies take
Of the 42 Carcinoma, Intraductal, Noninfiltrating studies recruiting now, 33 (79%) set no upper age limit and 5 (12%) stop at 75 or younger. 1 (2%) take children under 18. 33 (79%) are for women only and 0 (0%) for men only; 4 (10%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 1 (2%) | 0 (0%) |
| 18 | 22 (52%) | 5 (12%) |
| 30 | 27 (64%) | 7 (17%) |
| 40 | 35 (83%) | 9 (21%) |
| 50 | 41 (98%) | 9 (21%) |
| 65 | 40 (95%) | 9 (21%) |
| 75 | 38 (90%) | 9 (21%) |
| 85 | 36 (86%) | 8 (19%) |
Across all 286 studies, recruiting or not: 11% stop at 75 or younger and 5% at 65; 6% take children; 86% are for women only and <1% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Carcinoma, Intraductal, Noninfiltrating studies take
Of 36 phase 2 interventional studies under Carcinoma, Intraductal, Noninfiltrating, half reached primary completion within 56 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Phase 2 | 56 mo32–117 · 36 studies | — | — |
| Interventional, no phase | 69 mo30–134 · 47 studies | — | 69 mo30–148 · 44 studies |
| Observational | 60 mo46–86 · 30 studies | — | 60 mo35–86 · 28 studies |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 15, 2026.
Results posted2
- Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast CancerNov 2, 2026NCT03979508
- Ruxolitinib for Premalignant Breast DiseaseOct 16, 2026NCT02928978
Newly registered3
- Study of Oncology-Adapted Pain Reprocessing Therapy for Aromatase Inhibitor Associated Musculoskeletal Symptoms in Breast Cancer SurvivorsNov 12, 2026NCT07934173
- Agentic AI App and Home Bioimpedance Monitoring for Endocrine Therapy Adherence and Lymphedema in Breast Cancer SurvivorsNov 3, 2026NCT07911839
- Addressing Financial Hardship in AYA Cancer Survivors Through the Use of the New LIFT UP InterventionNov 2, 2026NCT07909525
Studies
Recruiting first, then most recently updated. Showing 50 of 286. Browse all 286 → or search them.
- Study of Oncology-Adapted Pain Reprocessing Therapy for Aromatase Inhibitor Associated Musculoskeletal Symptoms in Breast Cancer SurvivorsNot yet recruitingNCT07934173Not applicable
- Preoperative vs. Pathologic Size in Breast Cancer: A Prospective StudyRecruitingNCT065055771 country
- Agentic AI App and Home Bioimpedance Monitoring for Endocrine Therapy Adherence and Lymphedema in Breast Cancer SurvivorsNot yet recruitingNCT07911839Not applicable1 country
- Addressing Financial Hardship in AYA Cancer Survivors Through the Use of the New LIFT UP InterventionNot yet recruitingNCT07909525Not applicable
- DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as TreatmentRecruitingNCT06075953Phase 21 country
- Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In SituRecruitingNCT06218303Phase 11 country
- Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast CancerRecruitingNCT02918474Not applicable1 country
- Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal CarcinomaRecruitingNCT03909282Not applicable1 country
- Impact of COVID-19 Pandemic on Out-of-Pocket Costs, Lost Wages, and Unemployment in Patients With Breast Cancer Undergoing Breast SurgeryRecruitingNCT041695421 country
- Assessment of Biosignature Classification of DCIS for RadioTherapy Benefit Post Lumpectomy (ABCD RT)Not yet recruitingNCT07554573Phase 3
- CAN1012 in Pre-Malignant DCIS and LCISRecruitingNCT07408856Phase 11 country
- Personalized Prone Immobilization for Accelerated Partial Breast RadiotherapyRecruitingNCT07711847Not applicable1 country
- Women Informed to Screen Depending on Measures of Risk (Wisdom Study)RecruitingNCT02620852Not applicable1 country
- Study of 3-Day Partial Breast Radiation Therapy in Women With Breast CancerRecruitingNCT04084730Phase 21 country
- Novel Cavity Marking Technique in Breast Cancer Patients Undergoing Breast Conservation Surgery With Oncoplastic Reconstruction for the Delivery of Adjuvant Radiotherapy and Accuracy of Recommended Re-excisionsRecruitingNCT06903468Not applicable1 country
- Ultra Hypo-fractionated Adjuvant Whole Breast Radiation Therapy With Simultaneous Integrated Boost for Early-Stage Breast Cancer (H-ASSIST)RecruitingNCT06902311Phase 21 country
- Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving SurgeryRecruitingNCT07762924Phase 21 country
- Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving SurgeryRecruitingNCT07762885Phase 31 country
- Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk ReductionRecruitingNCT06195306Phase 21 country
- Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE TrialRecruitingNCT06184750Phase 21 country
- Identifying and Caring for Individuals With Inherited Cancer SyndromeRecruitingNCT04494945Not applicable1 country
- Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast CancerRecruitingNCT05941520Phase 21 country
- Impact of Dietary Inflammatory Potential on Breast Cancer RiskRecruitingNCT051784981 country
- Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast CancerRecruitingNCT03936478Phase 21 country
- Multimodal Imaging With FAPI-PET/MRI in Breast Carcinoma-In-Situ for Detection of Occult Invasive CancerRecruitingNCT06540872Phase 21 country
- Areola Preservation in NSM With Nipple InvolvementNot yet recruitingNCT07544134Not applicable1 country
- The PREDICT Registry:RecruitingNCT034489261 country
- HISMAR: Intraoperative Margin Assessment Using the Histolog® Scanner to Reduce Reoperation in Breast-Conserving SurgeryNot yet recruitingNCT07527468Not applicable1 country
- Breast Tumour Size Measurement by Field Cycling ImagingNot yet recruitingNCT074920431 country
- EXploring Inflammation and Social deTerminants Study in Breast Cancer PatientsRecruitingNCT074780161 country
- A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In SituRecruitingNCT04144023Phase 11 country
- A Patient Navigation Program for Addressing Disparities in Breast Cancer CareRecruitingNCT06350500Not applicable1 country
- Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast CancerRecruitingNCT04959474Not applicable1 country
- A Prospective CohorT Study of HandX - Assisted ENdoscopic MAstectomy: Feasibility and Safety (ATHENA I Study)RecruitingNCT07292246Not applicable1 country
- 5 vs. 9-day Course of Whole Breast Radiotherapy With Boost for Early-stage Breast CancerRecruitingNCT06961955Phase 21 country
- Avoiding Surgery in Estrogen Receptor Positive Atypical Ductal Hyperplasia and In-situ Carcinoma Treated With Endocrine Treatment TrialNot yet recruitingNCT07245316Not applicable1 country
- ASHBY: Accelerated Super-Hypofractionated Breast BrachytherapyRecruitingNCT06185205Phase 21 country
- A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.RecruitingNCT07095114Not applicable1 country
- Human-AI Collaborative INSIGHT Diagnostic Workflow for in Breast Cancer With Extensive Intraductal ComponentNot yet recruitingNCT07060599Not applicable1 country
- Hypofractionated Radiotherapy With Concomitant Tumor Bed Boost for Breast CancerRecruitingNCT069842501 country
- Robotic Nipple Sparing Mastectomy with Immediate ReconstructionNot yet recruitingNCT06860217Not applicable1 country
- Delayed Selective Sentinel Node Biopsy for Patients Undergoing Mastectomy for DCISRecruitingNCT05912569Not applicable1 country
- The Added Value of Contrast Enhanced Mammography to Standard Mammography in Assessing the Extent of DCISNot yet recruitingNCT06217458Not applicable1 country
- Preoperative Partial Breast Irradiation in Early-Stage Breast CancerRecruitingNCT06677944Phase 21 country
- Perioperative Mindfulness ProposalRecruitingNCT04049214Not applicable1 country
- Study of Radiation Therapy in Combination With Darolutamide + Degarelix in Intermediate Risk Prostate CancerNot yet recruitingNCT04176081Phase 21 country
- Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in SituRecruitingNCT04722692Phase 33 countries
- Excisional Vacuum-Assisted Breast BiopsyRecruitingNCT05932758Not applicable1 country
- Molecular Analysis of the Sloane ProjectEnrolling by invitationNCT058682521 country
- Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In SituRecruitingNCT05218044Not applicable1 country